Professional Marketing briefs

Shire CEO Angus Russell, seeking to stem concerns about an OIG investigation of his firm's ADHD sales and marketing practices, said such inquiries have “almost become standard practice” in this industry and that “at this stage, it's a general inquiry.” Shire revealed that it had been subpoenaed for information on Adderall XR, Daytrana and Vyvanse promotion.

Eli Lilly is trimming its osteoporosis, diabetes and neurosciences sales forces by a total of 191 jobs as part of a restructuring plan announced in September, Indianapolis Business Journal reports. The company intends to lay off 5,500 by 2011 in an effort to soften the blow when Zyprexa, which has $4.7 billion in global sales, goes off patent the same year.

Warner Chilcott completed its $3.1 billion acquisition of P&G's global branded prescription pharmaceuticals unit, securing a 1,200-person sales force and a portfolio worth $2.3 billion in annual revenue. The company, based in Ireland, now markets such former P&G products as blockbuster brand Actonel (risedronate) for osteoporosis and colitis drug Asacol (mesalamine).


You must be a registered member of MMM to post a comment.
close

Next Article in Features


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.

Email Newsletters